Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005) |
NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Seelos' application number 16/460,046 titled: "TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE". The allowed claims cover a method of using trehalose (SLS-005) to treat several neurodegenerative conditions including spinocerebellar ataxia (SCA), spinal and bulbar muscular atrophy (SBMA), dentatomral-pailidoluyssan atrophy (DRPLA), Pick's disease, corticobasaldegeneration (CBD), progressive supranuclear palsy (PSP), and frontotemporal dementia. About Trehalose Contact Information: View original content to download multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-receives-notice-of-allowance-for-an-additional-us-patent-for-trehalose-sls-005-301126928.html SOURCE Seelos Therapeutics, Inc. |
9/10/2020 9:00:00 AM |